Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GRT-C903 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | * GRT-C903 * GRT-R904 * nivolumab * ipilimumab |
| Phase 2 | EXPERIMENTAL | * GRT-C903 * GRT-R904 * nivolumab * ipilimumab Phase 2 for some patients includes a monthly or every two month treatment schedule |
| Name | Type | Description |
|---|---|---|
| GRT-C903 | BIOLOGICAL | a shared neoantigen cancer vaccine prime |
| GRT-R904 | BIOLOGICAL | a shared neoantigen cancer vaccine boost |
| nivolumab | BIOLOGICAL | anti-PD-1 monoclonal antibody |
| ipilimumab | BIOLOGICAL | anti-CTLA-4 monoclonal antibody |
Inclusion Criteria: * Provide a signed and dated informed consent form prior to initiation of study-specific procedures. * Patients with the indicated advanced or metastatic solid tumor as follows: 1. Microsatellite-stable colorectal cancer (MSS-CRC) who are currently receiving systemic treatmen...
Top 20 of 84 competitors
GRT-C903 is an investigational monoclonal antibody being studied for the treatment of Non-Small Cell Lung Cancer. It is a personalized cancer vaccine designed to target shared neoantigens in solid tumors. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GRT-C903 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this investigational monoclonal antibody for oncology applications, specifically in Non-Small Cell Lung Cancer.
GRT-C903 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation for Non-Small Cell Lung Cancer.
GRT-C903 has one completed Phase 1 clinical trial registered under NCT03953235, titled 'A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens.' The trial enrolled 39 participants and was conducted in the United States, involving patients with Non-Small Cell Lung Cancer and other solid tumors.
GRT-C903 is a personalized cancer vaccine targeting shared neoantigens. It is designed to treat solid tumors, including Non-Small Cell Lung Cancer. The drug is being studied as a monoclonal antibody-based vaccine approach in an ongoing clinical development program.